Psoriasis as a systemic disease

Grozdev, Ivan; Korman, Neil J.; Tsankov, Nikolaï

doi:10.1016/j.clindermatol.2013.11.001

Cited by 136 publications

(120 citation statements)

References 97 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Özellikle son yıllarda psoriaziste artmış obezite, metabolik sendrom ve kardiyovasküler hastalık riski ile ilgili birçok çalışma yapılmıştır. Psoriazisdeki artmış enflamasyonun epitelyal disfonksiyona neden olduğu ve buna bağlı olarak kardiyovasküler hastalık riskinde artışa neden olduğu düşünülmektedir 2,[14][15][16] . Ürik asit hipertansiyon, metabolik sendrom ve aterosklerotik kalp hastalıkları gibi birçok durum ile ilişkili olduğu gösterilen metabolik bir belirteçtir [6][7][8] .…”

Section: Discussionunclassified

The role of uric acid in metabolic syndrome in patients with psoriasis

Solak¹,

Dikicier²,

Erdem³

2017

TURKDERM

View full text Add to dashboard Cite

Background and Design:Psoriasis patients have increased risk of obesity, metabolic syndrome and cardiovascular disease. Uric acid is a metabolic marker associated with metabolic syndrome and cardiovascular diseases. Uric acid levels increase in psoriasis as well. The aim of this study was to investigate the role of uric acid in metabolic syndrome in patients with psoriasis. Materials and Methods: Chronic plaque psoriasis patients who presented to the dermatology outpatient clinics in a university-affiliated training and research hospital and age-and gender-matched healthy individuals were included in the study. Waist circumference, height and weight measurements in both groups were recorded, and body mass index was calculated. Serum uric acid, urea, creatinine, C-reactive protein, fasting blood glucose, high-density lipoprotein cholesterol, total cholesterol, triglyceride and insulin levels were determined. Metabolic syndrome and insulin resistance status were evaluated. The findings were compared statistically. Results: Seventy patients with chronic plaque psoriasis (37 females, 33 males) and 60 healthy individuals (31 females, 29 males) were included in the study. The prevalence of metabolic syndrome and uric acid levels were found to be higher in the psoriasis group than in control group (p=0.003 and p=0.008, respectively). Serum uric acid levels and Psoriasis Area and Severity Index scores were higher in psoriasis patients with metabolic syndrome than in those without metabolic syndrome when psoriasis patients were evaluated separately (p=0.041, p=0.024, respectively). A positive correlation was observed between abdominal circumference and serum uric acid levels in psoriasis patients (p=0.003, r=0.350). AbstractAmaç: Enflamatuvar bir hastalık olan psoriaziste son yıllarda obezite, metabolik sendrom ve kardiyovasküler hastalık riskinin arttığı gösterilmiştir. Ürik asit metabolik sendrom ve kardiyovasküler hastalıklarla ilişkili ve aynı zamanda psoriaziste arttığı bilinen metabolik bir belirteçtir. Psoriazis hastalarındaki artmış metabolik sendrom riskinde ürik asitin rol oynayıp oynamadığını araştırmayı amaçladık. Gereç ve Yöntem: Üniversite afiliye eğitim ve araştırma hastanesi dermatoloji polikliniğinde görülmüş olan kronik plak psoriazisli hastalar ile yaş ve cinsiyet uyumlu sağlıklı kontrol grubu çalışmaya alındı. Hasta ve kontrol grubunun bel çevresi, boy ve kilo ölçümü kaydedildi. Vücut kitle indeksleri hesaplandı. Serum ürik asit, üre, kreatinin, C-reaktif protein açlık glukoz, yüksek yoğunluklu lipoprotein kolesterol, total kolesterol, trigliserid ve insülin değerleri ölçümleri kaydedildi. Hasta ve kontrol grubunda metabolik sendrom varlığı ve insülin direnci değerlendirildi. Sonuçlar istatistiksel olarak karşılaştırıldı. Bulgular: Kronik plak psoriazisli 70 hasta (37 kadın, 33 erkek) ile 60 sağlıklı kontrol (31 kadın, 29 erkek) çalışmaya alındı. Psoriazis hastalarında metabolik sendrom sıklığının kontrol grubuna göre daha sık ve ürik asit düzeyinin daha yüksek olduğunu saptadık (p=0,003, p=0,008, sır...

show abstract

Section: Discussionunclassified

The role of uric acid in metabolic syndrome in patients with psoriasis

Solak¹,

Dikicier²,

Erdem³

2017

TURKDERM

View full text Add to dashboard Cite

show abstract

“…Łuszczyca to przewlekła choroba zapalna skóry, która dotyczy ok. 2-3% populacji [1], o podłożu immunologicznym i genetycznym [2]. W ok. 25% przypadków współistnieje z łuszczycowym zapaleniem stawów, co prowadzi do znacznego obniżenia jakości życia [3,4].…”

Section: Wprowadzenieunclassified

“…Psoriasis is a chronic inflammatory skin disease affecting approximately 2-3% of the population [1]. The condition has immunological and genetic background [2].…”

Section: Introductionmentioning

confidence: 99%

Challenges of biological therapy in patients with pustular psoriasis coexisting with psoriatic arthritis

Trelińska¹,

Woźniacka²,

Olejniczak-Staruch³

et al. 2017

View full text Add to dashboard Cite

“…Multidisciplinary and integrated approach to the disease has been targeted instead of treatment in disease management. This is reached by description of accompanying diseases and adaptation of treatment according to existing comorbidities [1][2][3][4]81 .…”

Section: Patient Evaluation/managementmentioning

confidence: 99%

“…Psoriasis, with a worldwide prevalence of 2-3%, is now assumed as a systemic chronic inflammatory disease accompanied by comorbidities while it was accepted as a disease limited only to the skin in the past 1 . Psoriasis and its comorbidities were the main focused topic at several sessions of the 73 rd Annual Meeting of the American Academy of Dermatology and, especially, systemic disease concept was emphasized 2 .…”

Section: Introductionmentioning

confidence: 99%

Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management

Kalkan¹

2017

TURKDERM

View full text Add to dashboard Cite

©Copyright 2017 by Turkish Society of Dermatology and Venereology Turkderm-Turkish Archives of Dermatology and Venereology published by Galenos Yayınevi. Öz IntroductionPsoriasis, with a worldwide prevalence of 2-3%, is now assumed as a systemic chronic inflammatory disease accompanied by comorbidities while it was accepted as a disease limited only to the skin in the past 1 . Psoriasis and its comorbidities were the main focused topic at several sessions of the 73 rd Annual Meeting of the American Academy of Dermatology and, especially, systemic disease concept was emphasized 2 . Therefore, recent publications suggest that the term psoriatic disease would be a better nomination instead of psoriasis 3 . In this review, learning screening recommendations developed for early detection and treatment of comorbidities as well as integrated, multidisciplinary approach for disease management have been targeted by reviewing psoriasis and accompanying comorbidities. Comorbidities are more frequently seen in 15% of psoriasis patients who have moderate to severe psoriasis due to increased inflammatory impact and common pathogenesis. Consistent monitoring and systemic treatment are required to prevent development of comorbidities. There are several Tüm dünyada %2-3 oranında görülme sıklığına sahip psoriazis, geçmişte sadece deriye sınırlı kabul edilirken, günümüzde birçok komorbiditenin eşlik ettiği kronik sistemik enflamatuvar bir hastalık olarak ele alınmaktadır. Orta-şiddetli düzeyde psoriazisi olanlarda daha sık görülen komorbiditelerle ilgili çeşitli sınıflamalar mevcuttur. Basit olarak klasik, kronik sistemik enflamasyonla ilişkili, yaşam tarzı ile ilgili ve tedavi ile ilgili olarak sınıflanabileceği gibi medikal komorbiditeler, psikiyatrik/psikolojik komorbiditeler ve komorbiditelere katkı yapan durumlar şeklinde de sınıflanabilmektedir. Bu derlemede psoriazis ve eşlik eden komorbiditelerin gözden geçirilmesiyle; komorbiditelerin erken tanı ve tedavisini sağlama, komorbiditilerin erken tespitine yönelik geliştirilen tarama önerilerini öğrenme ve hastalığın yönetiminde entegre, multidisipliner yaklaşım ile uzun dönem hastalık kontrolü ve hayat kalitesinde düzelme sağlamak hedeflenmektedir. Anahtar Kelimeler: Psoriazis, komorbidite, sistemik hastalık Psoriasis, with a worldwide prevalence of 2-3%, is now assumed as a systemic chronic inflammatory disease accompanied by comorbidities while it was accepted as a disease limited only to the skin in the past. There are several classifications of the comorbidities which are more common in patients with moderate to severe psoriasis. Simply, comorbidities can be classified as classic, emerging, related to lifestyle, related to treatment. They can also be categorized as medical comorbidities, psychiatric/psychologic comorbidities, and behaviors contributing to medical and psychiatric comorbidities. In this review, providing early diagnosis and treatment of comorbidities, learning screening recommendations for early detection and long-term disease control and improvemen...

show abstract

Psoriasis as a systemic disease

Cited by 136 publications

References 97 publications

The role of uric acid in metabolic syndrome in patients with psoriasis

The role of uric acid in metabolic syndrome in patients with psoriasis

Challenges of biological therapy in patients with pustular psoriasis coexisting with psoriatic arthritis

Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management

Contact Info

Product

Resources

About